Tumor Burden Measured by 18F-FDG PET/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma

Tumor Burden Measured by 18F-FDG PET/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma

Chimeric antigen receptor (CAR) T-cell therapy has exhibited promising clinical outcomes in treating relapsed/refractory (R/R) B-cell hematologic malignancies. Current studies have shown a close correlation between baseline tumor burden and therapeutic response in CAR-T cell therapy. However, the ro...

Full description

Bibliographic Details
Main Authors: Ruimin Hong, Elaine Tan Su Yin, Linqin Wang, Xin Zhao, Linghui Zhou, Guangfa Wang, Mingming Zhang, Houli Zhao, Guoqing Wei, Yiyun Wang, Wenjun Wu, Yafei Zhang, Fang Ni, Yongxian Hu, He Huang, Kui Zhao
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Oncology
Subjects:
chimeric antigen receptor T-cell therapy
non-Hodgkin lymphoma
metabolic tumor burden
FDG PET/CT
prognosis
adverse effects
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.713577/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.713577/full

Similar Items